GW Pharma (GWPH) PT Raised to $200 at Cowen

GW Pharma (GWPH) PT Raised to $227 at Stifel

Stifel analyst Paul Matteis raised the price target on GW Pharma (NASDAQ: GWPH) to $227.00 (from $191.00) while maintaining a Buy rating after spending time with management post 1Q print. The company reaffirmed views that the Epidiolex launch to date, considering all of the... More

GW Pharma (GWPH) PT Raised to $229 at Cantor Fitzgerald

Cantor Fitzgerald analyst Elemer Piros raised the price target on GW Pharma (NASDAQ: GWPH) to $229.00 (from $196.00) while maintaining a Overweight rating following Q1 results.

Piros commented, "The company reported the first full quarter of EPIDIOLEX revenues of $33.5 million. Additionally, GWPH reported positive... More

GW Pharma (GWPH) PT Raised to $218 at BofA/Merrill Lynch

BofA/Merrill Lynch analyst Tazeen Ahmad raised the price target on GW Pharma (NASDAQ: GWPH) to $218.00 (from $200.00) while maintaining a Buy rating.

Oppenheimer Upgrades GW Pharma (GWPH) to Outperform

Oppenheimer analyst Esther Rajavelu upgraded GW Pharma (NASDAQ: GWPH) from Perform to Outperform with a price target of $162.00 (from $234.00).

The analyst comments "GWPH reported strong Epidiolex uptake, driven by new patients, bolus 4Q patients, and conversion of most EAP/OLE patients to... More

GW Pharma (GWPH) Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX Oral Solution in Patients with Seizures Associated With TSC

GW Pharmaceuticals plc and its U.S. subsidiary Greenwich Biosciences Inc. (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced positive top-line results of a randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) CV in the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare and severe form of childhood-onset epilepsy. In this trial, EPIDIOLEX met its primary endpoint, which was the reduction in seizure frequency compared to baseline of the Epidiolex 25 mg/kg/day dose group vs placebo (p=0.0009).... More